Lilly, Hutchison In Potential $86.5 Million Deal To Co-Develop Cancer Drug In China
This article was originally published in PharmAsia News
Executive Summary
Eli Lilly and Chi-Med's Hutchison MediPharma subsidiary have signed an agreement to co-develop and market a small-molecule drug discovered by Hutchison, HMPL-013 (fruquintinib) for treating a variety of solid tumors.